JP2016511234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511234A5 JP2016511234A5 JP2015555412A JP2015555412A JP2016511234A5 JP 2016511234 A5 JP2016511234 A5 JP 2016511234A5 JP 2015555412 A JP2015555412 A JP 2015555412A JP 2015555412 A JP2015555412 A JP 2015555412A JP 2016511234 A5 JP2016511234 A5 JP 2016511234A5
- Authority
- JP
- Japan
- Prior art keywords
- flt
- antibody
- fragment
- binding
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 13
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 11
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 241000282693 Cercopithecidae Species 0.000 claims 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 238000000159 protein binding assay Methods 0.000 claims 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 2
- 208000010428 Muscle Weakness Diseases 0.000 claims 2
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 101150062285 PGF gene Proteins 0.000 claims 2
- 102100035194 Placenta growth factor Human genes 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010069632 Bladder dysfunction Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010062344 Congenital musculoskeletal anomaly Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023201 Joint contracture Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028311 Muscle hypertrophy Diseases 0.000 claims 1
- 230000006736 behavioral deficit Effects 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 230000012042 muscle hypertrophy Effects 0.000 claims 1
- 230000009756 muscle regeneration Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 206010039722 scoliosis Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361757571P | 2013-01-28 | 2013-01-28 | |
| US61/757,571 | 2013-01-28 | ||
| PCT/US2014/013402 WO2014117160A1 (en) | 2013-01-28 | 2014-01-28 | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018206297A Division JP2019023230A (ja) | 2013-01-28 | 2018-11-01 | デュシェンヌ型筋ジストロフィーの治療における抗−ｆｌｔ−１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511234A JP2016511234A (ja) | 2016-04-14 |
| JP2016511234A5 true JP2016511234A5 (enExample) | 2017-03-02 |
| JP6469022B2 JP6469022B2 (ja) | 2019-02-13 |
Family
ID=50073518
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555412A Active JP6469022B2 (ja) | 2013-01-28 | 2014-01-28 | デュシェンヌ型筋ジストロフィーの治療における抗−ｆｌｔ−１抗体 |
| JP2018206297A Pending JP2019023230A (ja) | 2013-01-28 | 2018-11-01 | デュシェンヌ型筋ジストロフィーの治療における抗−ｆｌｔ−１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018206297A Pending JP2019023230A (ja) | 2013-01-28 | 2018-11-01 | デュシェンヌ型筋ジストロフィーの治療における抗−ｆｌｔ−１抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9957324B2 (enExample) |
| EP (1) | EP2948476B1 (enExample) |
| JP (2) | JP6469022B2 (enExample) |
| KR (1) | KR102259255B1 (enExample) |
| CN (1) | CN104955843B (enExample) |
| AU (1) | AU2014209012B2 (enExample) |
| BR (1) | BR112015017242B1 (enExample) |
| CA (1) | CA2898998C (enExample) |
| EA (1) | EA037501B1 (enExample) |
| ES (1) | ES2676406T3 (enExample) |
| HK (1) | HK1213918A1 (enExample) |
| IL (1) | IL238588B (enExample) |
| MX (1) | MX360153B (enExample) |
| WO (1) | WO2014117160A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948164B1 (en) | 2013-01-28 | 2019-04-10 | Shire Human Genetic Therapies, Inc. | Placenta growth factor in treating duchenne muscular dystrophy |
| MA41899A (fr) * | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| US10738123B2 (en) | 2015-04-07 | 2020-08-11 | Shire Human Genetic Therapies, Inc. | Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia |
| CA2981961A1 (en) * | 2015-04-07 | 2016-10-13 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
| KR102019048B1 (ko) | 2017-02-06 | 2019-09-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법 |
| KR101886788B1 (ko) | 2017-02-07 | 2018-08-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| WO2023182657A1 (ko) | 2022-03-24 | 2023-09-28 | 주식회사 케이에스비튜젠 | 항-fetuin-b 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2377555A3 (en) * | 2004-11-18 | 2011-11-23 | Imclone LLC | Antibodies against vascular endothelial growth factor receptor-1 |
-
2014
- 2014-01-28 CN CN201480003714.6A patent/CN104955843B/zh active Active
- 2014-01-28 US US14/763,881 patent/US9957324B2/en active Active
- 2014-01-28 CA CA2898998A patent/CA2898998C/en active Active
- 2014-01-28 HK HK16101850.9A patent/HK1213918A1/zh unknown
- 2014-01-28 MX MX2015009690A patent/MX360153B/es active IP Right Grant
- 2014-01-28 JP JP2015555412A patent/JP6469022B2/ja active Active
- 2014-01-28 ES ES14704040.6T patent/ES2676406T3/es active Active
- 2014-01-28 AU AU2014209012A patent/AU2014209012B2/en active Active
- 2014-01-28 KR KR1020157021136A patent/KR102259255B1/ko active Active
- 2014-01-28 EP EP14704040.6A patent/EP2948476B1/en active Active
- 2014-01-28 BR BR112015017242-3A patent/BR112015017242B1/pt active IP Right Grant
- 2014-01-28 WO PCT/US2014/013402 patent/WO2014117160A1/en not_active Ceased
- 2014-01-28 EA EA201590720A patent/EA037501B1/ru unknown
-
2015
- 2015-05-03 IL IL238588A patent/IL238588B/en active IP Right Grant
-
2018
- 2018-04-12 US US15/951,937 patent/US20180312593A1/en not_active Abandoned
- 2018-11-01 JP JP2018206297A patent/JP2019023230A/ja active Pending
-
2020
- 2020-07-14 US US16/928,819 patent/US20210163603A1/en not_active Abandoned